A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study is designed as a long-term extension to the Phase 3 parent-study SM04690-OA-11. It
aims to evaluate the safety and efficacy of long-term use of lorecivivint (LOR) in subjects
with knee osteoarthritis (OA). The first 48 weeks will be single-blind and placebo-controlled
while the remainder of the study will be open-label and uncontrolled. Subjects must enroll no
later than 6 weeks following completion of the parent-study.